臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 51350136 在线人数 : 703 教育部委托研究计画计画执行:国立台湾大学图书馆

搜寻范围

进阶搜寻

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"lorence r m"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 1-16 / 16 (共1页)
1
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2022-06-27T07:02:08Z	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial	Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; Yang P.-C.; Miller V.A.
臺大學術典藏	2021-05-02T03:49:12Z	Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations	Chang G.-C.; Lam D.C.-L.; Tsai C.-M.; Chen Y.-M.; JIN-YUAN SHIH; Aggarwal S.; Wang S.; Kim S.-W.; Kim Y.-C.; Wahid I.; Li R.; Lim D.W.-T.; Sriuranpong V.; Chan R.T.-T.; Lorence R.M.; Carriere P.; Raabe C.; Cseh A.; Park K.
臺大學術典藏	2020-12-02T02:34:00Z	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial	Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; PAN-CHYR YANG; Miller V.A.
臺大學術典藏	2020-08-13T06:33:49Z	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial	Miller V.A.; Yang P.-C.; Lorence R.M.; Cong X.J.; Shahidi M.; Dudek A.Z.; Sequist L.V.; Yang J.C.H.; JIN-YUAN SHIH; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L.
臺大學術典藏	2020-08-13T06:33:29Z	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program	Spataro V.; Unk M.; Chih-Hsin Yang J.; Lorence R.M.; Carri?re P.; Cseh A.; Chang G.-C.; Gautschi O.; Liao W.-Y.; Peters S.;Curioni-Fontecedro A.;Nechushtan H.;Jin-Yuan Shih;Liao W.-Y.;Gautschi O.;Spataro V.;Unk M.;Chih-Hsin Yang J.;Lorence R.M.;Carri?Re P.;Cseh A.;Chang G.-C.; Peters S.; Curioni-Fontecedro A.; Nechushtan H.; JIN-YUAN SHIH
臺大學術典藏	2020-08-13T06:33:29Z	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program	Spataro V.; Unk M.; Chih-Hsin Yang J.; Lorence R.M.; Carri?re P.; Cseh A.; Chang G.-C.; Gautschi O.; Liao W.-Y.; Peters S.;Curioni-Fontecedro A.;Nechushtan H.;Jin-Yuan Shih;Liao W.-Y.;Gautschi O.;Spataro V.;Unk M.;Chih-Hsin Yang J.;Lorence R.M.;Carri?Re P.;Cseh A.;Chang G.-C.; Peters S.; Curioni-Fontecedro A.; Nechushtan H.; JIN-YUAN SHIH
臺大學術典藏	2020-05-26T09:27:07Z	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial	Miller V.A.;Yang P.-C;Lorence R.M;Cong X.J;Shahidi M;Dudek A.Z;Sequist L.V;Ho C.-L;Chang G.-C;Yu C.-J;Ou S.H.I;Tsai C.-M;Hsia T.-C;Su W.-C;Shih J.-Y;Chih-Hsin Yang; CHIH-HSIN YANG; Shih J.-Y; Su W.-C; Hsia T.-C; Tsai C.-M; Ou S.H.I; Yu C.-J; Chang G.-C; Ho C.-L; Sequist L.V; Dudek A.Z; Shahidi M; Cong X.J; Lorence R.M; Yang P.-C; Miller V.A.
臺大學術典藏	2020-05-26T09:27:07Z	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial	Miller V.A.;Yang P.-C;Lorence R.M;Cong X.J;Shahidi M;Dudek A.Z;Sequist L.V;Ho C.-L;Chang G.-C;Yu C.-J;Ou S.H.I;Tsai C.-M;Hsia T.-C;Su W.-C;Shih J.-Y;Chih-Hsin Yang; CHIH-HSIN YANG; Shih J.-Y; Su W.-C; Hsia T.-C; Tsai C.-M; Ou S.H.I; Yu C.-J; Chang G.-C; Ho C.-L; Sequist L.V; Dudek A.Z; Shahidi M; Cong X.J; Lorence R.M; Yang P.-C; Miller V.A.
臺大學術典藏	2020-05-26T09:27:07Z	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial	Chih-Hsin Yang;Lorence R.M;Cong X.J;Shahidi M;Chao T.-Y;Tan E.-H;Crino L;Heo D.S;Sun Y;Wang M;Su W.-C;Zhou C;Kim S.-W;Park K;Chen Y.-M;Cadranel J;Hirsh V;Miller V.A; Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:27:07Z	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial	Chih-Hsin Yang;Lorence R.M;Cong X.J;Shahidi M;Chao T.-Y;Tan E.-H;Crino L;Heo D.S;Sun Y;Wang M;Su W.-C;Zhou C;Kim S.-W;Park K;Chen Y.-M;Cadranel J;Hirsh V;Miller V.A; Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:24Z	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation?�Positive Advanced NSCLC: Findings From a Global Named Patient Use Program	Chang G.-C.;Cseh A;Carri?re P;Lorence R.M;Chih-Hsin Chih-Hsin Yang;Unk M;Spataro V;Gautschi O;Liao W.-Y;Shih J.-Y;Nechushtan H;Curioni-Fontecedro A;Peters S; Peters S; Curioni-Fontecedro A; Nechushtan H; Shih J.-Y; Liao W.-Y; Gautschi O; Spataro V; Unk M; Chih-Hsin CHIH-HSIN YANG; Lorence R.M; Carrière P; Cseh A; Chang G.-C.
臺大學術典藏	2020-05-26T09:26:24Z	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation?�Positive Advanced NSCLC: Findings From a Global Named Patient Use Program	Chang G.-C.;Cseh A;Carri?re P;Lorence R.M;Chih-Hsin Chih-Hsin Yang;Unk M;Spataro V;Gautschi O;Liao W.-Y;Shih J.-Y;Nechushtan H;Curioni-Fontecedro A;Peters S; Peters S; Curioni-Fontecedro A; Nechushtan H; Shih J.-Y; Liao W.-Y; Gautschi O; Spataro V; Unk M; Chih-Hsin CHIH-HSIN YANG; Lorence R.M; Carrière P; Cseh A; Chang G.-C.
臺大學術典藏	2018	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program	Peters S.;Curioni-Fontecedro A.;Nechushtan H.;Shih J.-Y.;Wei-Yu Liao;Gautschi O.;Spataro V.;Unk M.;Chih-Hsin Yang J.;Lorence R.M.;Carri?Re P.;Cseh A.;Chang G.-C.; Peters S.; Curioni-Fontecedro A.; Nechushtan H.; Shih J.-Y.; WEI-YU LIAO; Gautschi O.; Spataro V.; Unk M.; Chih-Hsin Yang J.; Lorence R.M.; Carri?re P.; Cseh A.; Chang G.-C.
臺大學術典藏	2018	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program	Peters S.;Curioni-Fontecedro A.;Nechushtan H.;Shih J.-Y.;Wei-Yu Liao;Gautschi O.;Spataro V.;Unk M.;Chih-Hsin Yang J.;Lorence R.M.;Carri?Re P.;Cseh A.;Chang G.-C.; Peters S.; Curioni-Fontecedro A.; Nechushtan H.; Shih J.-Y.; WEI-YU LIAO; Gautschi O.; Spataro V.; Unk M.; Chih-Hsin Yang J.; Lorence R.M.; Carri?re P.; Cseh A.; Chang G.-C.
臺大學術典藏	2013	Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: Results of a randomized phase iib/iii trial (lux-lung 1)	Hirsh V;Cadranel J;Cong X.J;Fairclough D;Finnern H.W;Lorence R.M;Miller V.A;Palmer M;Chih-Hsin Yang; Hirsh V; Cadranel J; Cong X.J; Fairclough D; Finnern H.W; Lorence R.M; Miller V.A; Palmer M; CHIH-HSIN YANG
臺大學術典藏	2013	Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: Results of a randomized phase iib/iii trial (lux-lung 1)	Hirsh V;Cadranel J;Cong X.J;Fairclough D;Finnern H.W;Lorence R.M;Miller V.A;Palmer M;Chih-Hsin Yang; Hirsh V; Cadranel J; Cong X.J; Fairclough D; Finnern H.W; Lorence R.M; Miller V.A; Palmer M; CHIH-HSIN YANG

显示项目 1-16 / 16 (共1页)
1
每页显示[10|25|50]项目